

## **ZHANG Zong-Kang (Ph.D.)**

### **Academic qualifications:**

- 2000-2005: Bachelor, Major in clinical medicine, Shanghai Medical College, Fudan University, Shanghai, China
- 2005-2007: Master, Major in hand surgery, Shanghai Medical College, Fudan University, Shanghai, China
- 2008- 2013: Ph.D., Major in rehabilitation science, Dept. of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong

### **Previous academic positions held:**

- 2005-2007: Surgeon Intern, Huashan Hospital, Fudan University, Shanghai, China
- 2008-2008: Research Assistant, Dept. of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong
- 2010-2011: Visiting Scientist, Dept. of Biomedical Engineering, Stony Brook University, NY, USA
- 2011-2013: Research Associate (part-time), Dept. of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong
- 2013-2014: Research Assistant, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
- 2014- 2017: Postdoctoral Fellow, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong

### **Present academic position:**

- 2018- now: Research Associate, School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong

### **Previous relevant research work:**

Natural product- and genetic modulation-based strategies in musculoskeletal diseases

### **Publication records:**

#### **Section A-Five most representative publications in the recent five years (# Co-first author)**

1. **Zhang ZK**, Li J, Guan D, Liang C, Zhuo Z, Liu J, Lu A, Zhang G, Zhang BT. A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration. *Journal of Cachexia, Sarcopenia and Muscle* 2018, 9(3):613-626.
2. Liang C, Wang L, **Zhang ZK**<sup>#</sup>, Wang C, Li J, He B, Zhu H, Zhang BT, Li F, Lu A, Zhang G. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for

- therapeutic genome editing of VEGF-A in osteosarcoma. *Biomaterials* 2017, 147:68-85.
3. Guo B, **Zhang ZK**<sup>#</sup>, Liang C, Li J, Liu J, Lu A, Zhang BT, Zhang G. Molecular Communication from Skeletal Muscle to Bone: A Review for Muscle-Derived Myokines Regulating Bone Metabolism. *Calcified Tissue International* 2017, 100(2):184-192.
  4. He B, **Zhang ZK**<sup>#</sup>, Liu J, He YX, Tang T, Li J, Guo BS, Lu AP, Zhang BT, Zhang G. Bioinformatics and Microarray Analysis of miRNAs in Aged Female Mice Model Implied New Molecular Mechanisms for Impaired Fracture Healing. *International Journal of Molecular Sciences* 2016, 17(8): E1260.
  5. **Zhang ZK**, Li J, Liu J, Guo B, Leung A, Zhang G, Zhang BT. Icaritin requires Phosphatidylinositol 3 kinase (PI3K)/Akt signaling to counteract skeletal muscle atrophy following mechanical unloading. *Scientific Reports* 2016; 6:20300.

**Publications: Section B - Five representative publications beyond the recent five-year period with the latest publication entered first**

6. Wang Q, Zheng YP, Wang XY, **Zhang ZK**, Guo X. Ultrasound evaluation of site-specific effect of simulated microgravity on articular cartilage. *Ultrasound Med Biol.* 2010, 36: 1089-97.
7. **Zhang ZK**, Lao J, Zhao X. Clinical analysis of 71 cases of glomus tumors. *Chin J Hand Surg.* 2007, 23(3): 136-38.
8. **Zhang ZK**, Lao J. Review: glomus tumors in hand and a case report. *Chin J Bone tumor & Bone Disease.* 2006, 5(4): 239-41.

**Award:**

1. **Zhang ZK**, Guo X. The Nerve Lengthening Device. The TIIIA Award for the best Invention. Taiwan Invention & Innovation Industry Association, 3CIIs, 2011

**Patents:**

1. **Zhang ZK**, Guo X. L shape hexagon key for distraction precision control in a nerve lengthening device. Provisional Application for patent of US, EFS ID: 14552545.
2. **Zhang ZK**, Guo X. Peripheral nerve lengthening device and methods for repair nerve defect. Provisional Application for patent of US, EFS ID: 14552595.